ライフサイエンスコーパス: cycloserine

1 al therapy, the most promising of which is D-cycloserine.

2 s including beta-lactams, polymyxin B, and d-cycloserine.

3 he algD operon undergoes high induction by D-cycloserine.

4 a complete lack of PalgD-cat induction by D-cycloserine.

5 echanism of alanine racemase inactivation by cycloserine.

6 dex increased 100% in the presence of 2 mm l-cycloserine.

7 tuberculosis fails to become resistant to D-cycloserine.

8 mptoms worsen, as previously reported with D-cycloserine.

9 ontrolled trial of 50 mg and 100 mg/day of D-cycloserine.

10 anidine and enrichment with penicillin and D-cycloserine.

11 ith response of negative symptoms to 50-mg D-cycloserine.

12 ularly for toxic second-line drugs such as D-cycloserine.

13 cine(B) site on the NMDA receptor, such as d-cycloserine.

14 in comparison with the enzyme inactivated by cycloserine.

15 ion of the NMDA receptor partial coagonist d-cycloserine.

16 1 to either iTBS plus placebo or iTBS plus D-cycloserine (100 mg) for the first 2 weeks followed by i

17 sessions, the participants received either D-cycloserine, 100 mg, or a placebo.

18 e mean reduction in negative symptoms with D-cycloserine (23%) was significantly greater than with pl

19 d-cycloserine (25 or 50 mg) or placebo was taken 1 hour be

20 microg/ml; clarithromycin, 1.25 microg/ml; D-cycloserine, 25 microg/ml; ethambutol, 20 microg/ml; and

21 Single administration of D-cycloserine (320 or 1000 microgram/kg) significantly imp

22 received linezolid, with a subset receiving cycloserine (5), clofazimine (5), delamanid (4), and bed

23 rtual reality exposure were augmented with D-cycloserine (50 mg) or alprazolam (0.25 mg) in a double-

24 ia for deficit syndrome were randomized to D-cycloserine, 50 mg/d (n=23) or placebo (n=24) added to t

25 High-dose D-cycloserine (8000 microgram/kg) or MK-801 (10-32 microgr

26 Finally, the effect of D-cycloserine, a cognitive enhancer that clinically enhanc

27 The authors examined whether D-cycloserine, a partial agonist at the glutamatergic N-me

28 In a preliminary dose-finding study, D-cycloserine, a partial agonist at the glycine modulatory

29 D-Cycloserine, a partial agonist at the glycine recognitio

30 This study examined whether d-cycloserine, a partial agonist at the N-methyl-D-asparta

31 d-cycloserine, a partial agonist at the N-methyl-d-asparta

32 lfactory threat extinction in aged rats by D-cycloserine, a partial NMDAR agonist, suggests that the

33 Cycloserine acts as a suicide inhibitor of alanine racem

34 The effects of D-cycloserine added to clozapine were assessed and compare

35 ted that the NMDA receptor partial agonist d-cycloserine administered after pavlovian extinction of c

36 Systemic D-cycloserine also selectively reduced intake of quinine-a

37 osure therapy for SAD may be enhanced with d-cycloserine, an agonist at the glutamatergic N-methyl-d-

38 Pretreatment with L-cycloserine, an inhibitor of de novo ceramide synthesis,

39 -propanol and, to a much lesser extent, by L-cycloserine, an inhibitor of de novo ceramide synthesis.

40 l-Cycloserine, an inhibitor of gSPT, inhibited the endocyt

41 Preincubation of cells with either L-cycloserine, an inhibitor of serine palmitoyltransferase

42 l-Cycloserine, an inhibitor that blocks serine palmitoyltr

43 ith an average of 5.3+/-1.3 drugs, including cycloserine, an injectable drug, and a fluoroquinolone.

44 anion drugs included linezolid, clofazimine, cycloserine and a fluoroquinolone.

45 Susceptibility was also increased to cycloserine and bacitracin, but not to fosfomycin or val

46 de, para-aminosalicylic acid, linezolid, and cycloserine and compared with Bactec MGIT results for py

47 e adduct is similar to that formed between d-cycloserine and d-a-AT or alanine racemase (Ala-Rac) in

48 o inhibitors of sphingolipid biosynthesis, L-cycloserine and fumonisin B1, prevented the observed acc

49 ted the assay by performing it to identify D-Cycloserine and furan-based benzene-derived compounds wi

50 Mechanism-based inhibitors such as cycloserine and gabaculine can inactivate aminotransfera

51 mbined with data from previous trials with D-cycloserine and glycine, suggest that agonists at the gl

52 reacts with the nucleophilic serine and that cycloserine and lactone rings of LTV are opened.

53 no overall differences in symptoms between D-cycloserine and placebo at any time.

54 differences between glycine and placebo or D-cycloserine and placebo subjects on the average cognitio

55 re between glycine and placebo subjects or D-cycloserine and placebo subjects.

56 pressant efficacy of ketamine, and perhaps D-cycloserine and rapastinel, holds promise for future glu

57 rtial agonists at the NMDA coagonist site, d-cycloserine and rapastinel, significantly reduced depres

58 g effects of extended training, as well as d-cycloserine and yohimbine treatment.

59 inhibitors of de novo ceramide synthesis (l-cycloserine) and CerS (fumonisin B(1)) in cell viability

60 ncomycin, ristocetin), peptides (bacitracin, cycloserine), and chloramphenicol were found to differ s

61 e synthesis, fumonisin B(1), myriocin, and l-cycloserine, and 4-HPR transiently activated serine palm

62 anion drugs included linezolid, clofazimine, cycloserine, and a fluoroquinolone.

63 Glycine site agonists were glycine, D-cycloserine, and aminocyclopropane-carboxylic acid.

64 acin, ethionamide, para-aminosalicylic acid, cycloserine, and linezolid.

65 ctamase in M. xanthus, such as ampicillin, D-cycloserine, and phosphomycin, accelerates the onset of

66 d loss of function conferred resistance to D-cycloserine, and susceptibility to the drug was partiall

67 et cell wall synthesis such as ethambutol, D-cycloserine, and vancomycin.

68 lyzed) treated with fosfomycin, D-boroAla, D-cycloserine, and vancomycin.

69 D-cycloserine appears to enhance the benefits of exposure

70 upport for the use of short-term dosing of d-cycloserine as an adjunctive intervention to exposure th

71 These data provide support for the use of D-cycloserine as an augmentation of behavior therapy for O

72 nking, and support testing of D-serine and D-cycloserine as immediately accessible, FDA-approved drug

73 The median CSF concentrations of cycloserine at 2 and 6 hours were 15.90 and 15.10 ug/mL

74 d consecutive 2-week trials of placebo and D-cycloserine at 5, 15, 50, and 250 mg/day.

75 ions at baseline or with concentrations of D-cycloserine at weeks 4 and 8.

76 d-cycloserine augmentation of CBT did not confer additiona

77 Glycine or D-cycloserine augmentation of psychotropic drug treatment

78 D-cycloserine augmentation reduced cortisol and startle re

79 D-Cycloserine-augmented and placebo-augmented CBT were ass

80 ng of plant metabolites within the ATP and D-cycloserine binding pockets of Ddl.

81 0 min, followed by inoculation onto modified cycloserine cefoxitin fructose agar with and without hor

82 for 10 min before inoculation onto modified cycloserine, cefoxitin, and fructose agar with horse blo

83 Cycloserine-cefoxitin fructose agar (CCFA), CCFA with ho

84 horse blood and taurocholate (CCFA-HT), and cycloserine-cefoxitin mannitol broth with taurocholate a

85 have developed a reduced-cost substitute for cycloserine-cefoxitin-fructose agar (CCFA), which is an

86 e produced by Clostridium difficile grown on cycloserine-cefoxitin-fructose agar (CCFA).

87 dvanced Clinical Diagnostics) and culture on cycloserine-cefoxitin-fructose agar followed by determin

88 iated disease were prospectively cultured on cycloserine-cefoxitin-fructose agar following alcohol sh

89 cile spores, at a rate comparable to that in cycloserine-cefoxitin-fructose broth.

90 conferring four-fold higher resistance to D-cycloserine compared to ddl6.

91 X-ray structure of the MGL.l-cycloserine complex has been solved at 1.6 A resolution.

92 e precursors isolated after treatment with d-cycloserine consisted entirely of N-glycolyl muropeptide

93 isolated from M. tuberculosis treated with d-cycloserine contained only N-glycolylmuramyl-tripeptide

94 Thus, we wondered if d-cycloserine could improve sociability in 4-week old Balb

95 , and levofloxacin (Lfx) and reinforced with cycloserine (Cs) and clofazimine (Cfz), delamanid (Dlm)

96 glutamic acid, aspartyl-histidine (Asp-His), cycloserine (cSer), and arginine, which provided a stepw

97 Chlamydia growth is inhibited by D-cycloserine (DCS) and in vitro analysis provided evidenc

98 ine and D-serine (DS), the partial agonist D-cycloserine (DCS) and the antagonist 5,7-dichlorokynuren

99 Whether and under which conditions D-cycloserine (DCS) augments the effects of exposure-based

100 d-Cycloserine (DCS) is a broad-spectrum antibiotic that in

101 D-cycloserine (DCS) is an N-methyl-D-aspartate (NMDA) rece

102 effects of enhancing NMDAR signaling using d-cycloserine (DCS) on a recently developed LTP EEG paradi

103 ear evidence for an augmentation effect of D-cycloserine (DCS) on exposure therapy for anxiety disord

104 ory processes, whereas the partial agonist D-cycloserine (DCS) potentiates both learning and extincti

105 ficacy of augmenting behavior therapy with D-cycloserine (DCS) to reduce tic severity in a placebo-co

106 rt here that inactivation of the predicted d-cycloserine (DCS) transporter gene cycA resensitized met

107 ntextual fear conditioning was reversed by D-Cycloserine (DCS) treatment.

108 nxiety disorders, the supplementary use of D-cycloserine (DCS), a partial agonist at the glutamatergi

109 Here we evaluate the ability of D-cycloserine (DCS), a partial agonist at the strychnine-i

110 tracellular Mg2+ concentration or applying d-cycloserine (DCS), a partial agonist of the GluN glycine

111 D-cycloserine (DCS), a partial agonist of the glycine co-a

112 The discovery of d-cycloserine (DCS), a partial agonist of the NMDA recepto

113 Specifically, D-cycloserine (DCS), a partial agonist of the NMDA-associa

114 nction have resulted in the development of d-cycloserine (DCS), a partial glutamatergic N-methyl-D-as

115 It is unclear whether d-cycloserine (DCS), a partial N-methyl-d-aspartate agonis

116 riments with rat subjects examined whether D-cycloserine (DCS), a partial NMDA agonist, facilitates t

117 hydrocortisone (HC), a corticosteroid, and D-Cycloserine (DCS), an N-methyl-D-aspartate receptor part

118 The effect of D-cycloserine (DCS), an NMDA partial agonist, on extinctio

119 ive efficacies of NR1 agonists glycine and d-cycloserine (DCS), and found efficacy to be dependent on

120 s to determine if a novel pharmacotherapy, D-cycloserine (DCS), enhanced the efficacy of the psychoth

121 studies for three pharmacological agents [d-cycloserine (DCS), glucocorticoids (GCs), and L-DOPA] wi

122 of the glycineB receptor partial agonist, D-cycloserine (DCS), has been shown to enhance the consoli

123 RSA) can be enhanced by the alanine analog d-cycloserine (DCS), which blocks alanine racemase (Alr1)

124 We tested the hypothesis that d-cycloserine (DCS), which enhances extinction in other pr

125 Moreover, D-cycloserine (DCS), which facilitates fear extinction, se

126 In this regard, administration of d-cycloserine (DCS), which is a glycine site NMDA receptor

127 ation of the NMDA receptor partial agonist D-cycloserine (DCS).

128 The effects of daily D-cycloserine (DCS; a partial agonist of the NMDA receptor

129 either NMDA receptor agonists/antagonists (D-cycloserine/dextromethorphan), dopamine type 2 receptor

130 D-Cycloserine did not augment a full course of comprehensi

131 were administered three different doses of D-cycloserine during each of three 2-week periods.

132 D-aspartate receptor modulators (ketamine, D-cycloserine), electroconvulsive therapy, and transcrania

133 analyses, alprazolam impaired recovery and D-cycloserine enhanced virtual reality outcome in patients

134 D-Cycloserine exhibits partial agonist activity at the gly

135 ial of current formulations of glycine and D-cycloserine failed to show an overall benefit.

136 vivo by treating prediabetic ZDF rats with L-cycloserine for 2 weeks.

137 There was no advantage of D-cycloserine for PTSD symptoms in primary analyses.

138 Seven dropouts occurred in the D-cycloserine group and 1 in the placebo group.

139 The iTBS plus D-cycloserine group had greater improvements in MADRS scor

140 At posttreatment, the D-cycloserine group had the lowest cortisol reactivity and

141 tment-specific enhancer of outcome for the D-cycloserine group only.

142 ical response were higher in the iTBS plus D-cycloserine group than in the iTBS plus placebo group (7

143 ly more improved at mid-treatment, and the D-cycloserine group's depressive symptoms were significant

144 Relative to the placebo group, the D-cycloserine group's OCD symptoms were significantly more

145 Following administration of D-cycloserine, haloperidol, and bromocriptine, healthy par

146 These results show that at low doses, D-cycloserine has cognition-enhancing properties in this m

147 D-Cycloserine has cognitive benefits for patients with Alz

148 d-cycloserine has the therapeutic properties of a desired

149 ursodeoxycholic acid, tryptophan, L-valine, cycloserine, hypoxanthine, and 4-O-Methylmelleolide conc

150 d-Cycloserine improved measures of impaired sociability in

151 tive symptoms, whereas the partial agonist D-cycloserine improved negative symptoms of patients takin

152 Thus, d-cycloserine improves both sociability and stereotypic be

153 ant M. smegmatis strains were inhibited by D-cycloserine in a concentration-dependent manner.

154 Participants receiving d-cycloserine in addition to exposure therapy reported sig

155 Further controlled studies of D-cycloserine in autism appear warranted.

156 f the transaminase pathway) in the case of d-cycloserine, in contrast to results obtained using the w

157 We additionally report the L- and D-cycloserine inactivated crystal structures of Bacillus s

158 tic adduct, a scheme similar to that seen in cycloserine inactivation of aminotransferases.

159 illus stearothermophilus alanine racemase on cycloserine inactivation.

160 transport, whereas d-alanine, glycine, and d-cycloserine inhibit CycA-mediated d-serine transport.

161 intake of quinine-adulterated alcohol, and D-cycloserine inhibited NAcore HA-NMDARs in vitro.

162 The chemical means by which cycloserine inhibits alanine racemase is unknown.

163 These observations indicate that cycloserine inhibits alanine racemase production of D-Al

164 y results suggest that neither glycine nor D-cycloserine is a generally effective therapeutic option

165 Cycloserine is a known alanine racemase suicide substrat

166 D-cycloserine is an antibiotic used for six decades withou

167 D-cycloserine is an antibiotic which targets sequential ba

168 D-Cycloserine is an effective second-line drug against Myc

169 D-cycloserine is associated with a small augmentation effe

170 We have shown that cell wall stress (e.g. d-cycloserine) is a potent inducer of the algD operon.

171 is clinical trial indicate that adjunctive D-cycloserine may be a promising strategy for enhancing tr

172 erate to high CSF penetration, linezolid and cycloserine may be effective drugs for TBM treatment, wh

173 onists or antagonists, namely (+/-)HA-966, D-cycloserine, MDL-29,951, DPCQ, MNQX or L-701 252 were ab

174 baseline score, 30.3 [4.2]) and iTBS plus D-cycloserine (mean [SD] baseline score, 30.4 [4.5]).

175 odulators are covered, including D-serine, D-cycloserine, memantine, and glycine and first-generation

176 oligonucleotides covalently attached to a D-cycloserine molecule, whereby entry into the mycobacteri

177 stant to amikacin, bedaquiline, clofazimine, cycloserine, moxifloxacin, and pyrazinamide, while it in

178 When strain PAO1 was exposed to d-cycloserine, MucA was degraded within just 10 min, and s

179 rsely, inhibitors of ceramide biosynthesis L-cycloserine, myriocin and ARN14494 reduced ceramide prod

180 esis via serine palmitoyl-CoA transferase (L-cycloserine, myriocin or ARN14494) were used as a therap

181 either 250 mg of the partial NMDA agonist d-cycloserine (n=20) or matching placebo capsules (n=27).

182 or characterization of the in vivo effect of cycloserine on Escherichia coli.

183 There was a significant dose effect of D-cycloserine on scores on the Scale for the Assessment of

184 In the present study, the effects of D-cycloserine on spatial short-term memory deficits in mon

185 The authors assessed the effects of D-cycloserine on the core symptom of social impairment in

186 re, we examined the impact of D-serine and D-cycloserine on this aversion-resistant alcohol intake (t

187 l-Cycloserine, on the other hand, utilizes a number of alt

188 of virtual reality exposure augmented with D-cycloserine or alprazolam, compared with placebo, in red

189 ol (as compared to ethambutol alone) or as D-cycloserine or biotin covalent adducts without the prese

190 de substrate was eliminated by addition of d-cycloserine or blocked by addition of vancomycin.

191 D-cycloserine or CIQ (GluN2C/GluN2D positive allosteric mo

192 were randomly assigned to receive 50 mg of D-cycloserine or placebo 1 hour before each of five exposu

193 ion, participants received single doses of d-cycloserine or placebo.

194 ur E. coli strains exposed to ciprofloxacin, cycloserine, or nitrofurantoin and identify 812 resistan

195 ized clinical trial of adjunctive glycine, D-cycloserine, or placebo conducted at four sites in the U

196 In addition, D-cycloserine, phosphomycin, and hen egg-white lysozyme al

197 al Impressions-Severity indicated that the d-cycloserine plus CBT group and the placebo plus CBT grou

198 ed in a 1:1 ratio to either 10 sessions of d-cycloserine plus CBT or placebo plus CBT.

199 re randomized in a double-blind fashion to d-cycloserine plus CBT or placebo plus CBT.

200 sed and compared with previous results for D-cycloserine plus conventional neuroleptics.

201 Treatment of EAE mice with l-cycloserine prevented the increase in C(16:0)-Cer and iN

202 A966 and clonidine, but not propranolol or D-cycloserine, prevented FG7142-associated spatial working

203 The improvement of negative symptoms with D-cycloserine previously observed in patients receiving ty

204 alanine:D-alanine ligase by the antibiotic D-cycloserine proceeds via a distinct phosphorylated form

205 -week old Swiss Webster mice; furthermore, d-cycloserine reduced their intensity.

206 he SANS total score for patients receiving D-cycloserine relative to patients receiving placebo.

207 Serum concentrations of D-cycloserine, relevant amino acids, and homovanillic acid

208 We also show that D-cycloserine rescues the cognitive deficits observed in f

209 nimize the severe fitness costs of primary D-cycloserine resistance conferring mutations.

210 overproduction is a potential mechanism of D-cycloserine resistance in clinical isolates of M. tuberc

211 results show that one of the mechanisms of D-cycloserine resistance in M. smegmatis involves the over

212 To analyze the genetic determinants of D-cycloserine resistance in mycobacteria, a library of a r

213 Incorporation of D-cycloserine resistance in novel molecular diagnostics co

214 st that the ultra-low rate of emergence of D-cycloserine resistance mutations is the dominant biologi

215 The D-cycloserine resistance phenotype in the recombinant clon

216 A was necessary and sufficient to confer a D-cycloserine resistance phenotype.

217 Cycloserine resulted in a dramatic lowering of both D-Al

218 ing NMDAR function with the NMDAR co-agonist cycloserine reversed electrophysiological and behavioral

219 al derivative (arising from either isomer of cycloserine) saturated at the C4' carbon position.

220 12 via CycA, the d-alanine transporter and d-cycloserine sensitivity locus.

221 D-cycloserine shifted decision-making towards a more optim

222 Finally, the substrate reduction drug L-cycloserine significantly decreased the level of the pro

223 ne in a multicopy vector were resistant to D-cycloserine, suggesting that AlrA overproduction is a po

224 resulted in poor induction of PalgD-cat by D-cycloserine, suggesting that it also plays a role in the

225 atic assays using recombinant proteins and D-cycloserine susceptibility indicate that the A365V mutat

226 D-serine and D-cycloserine, the NMDAR activators at the glycine site, a

227 t neither extended extinction training nor d-cycloserine treatment improved 129S1 extinction.

228 In this pilot study, D-cycloserine treatment resulted in significant improvemen

229 ation of the NMDA receptor partial agonist D-cycloserine, under the same behavioural conditions, did

230 posed to low concentrations of fosfomycin, d-cycloserine, vancomycin, and nisin, indicating a wide-sp

231 nd, placebo-controlled trial investigating D-cycloserine versus placebo augmentation of behavior ther

232 Although D-cycloserine was associated with a 24%-33% faster rate of

233 D-Cycloserine was associated with significant improvement

234 A prosocial effect of d-cycloserine was observed at a dose as low as 32.0mg/kg i

235 with glycine, l-alanine, l-norvaline, and l-cycloserine was performed by pre-steady-state stopped-fl

236 was used in the first clinical trial, and D-cycloserine was used in the second one.

237 Enrichment with D-cycloserine was used to identify Escherichia coli auxotr

238 d-Cycloserine was well tolerated at most of the doses used

239 As a result, fosfomycin and D-cycloserine were added to the group of peptidoglycan syn

240 and alr exhibited increased resistance to D-cycloserine when cultured in vitro.

241 nd ddl7 conferred high level resistance to D-cycloserine when expressed in Escherichia coli with ddl7

242 D-cycloserine, when paired with familiarity training sessi

243 activity was partially (64%) inhibited by D-cycloserine, whereas host alanine racemase activity was

244 which blocks palmitoyl-CoA synthesis, and L-cycloserine, which blocks SPT activity, completely block

245 SRT experiments in the Twi mouse utilized l-cycloserine, which inhibits an enzyme several steps upst

246 ound that overlapped with genes induced by d-cycloserine, which is known to activate algD expression.